Goserelin Mitigates Risk of Ovarian Failure, Improves Breast Cancer Survival Rate

Share this content:
Previous analysis of the SWOG S0230/POEMS study suggested that goserelin improves survival rates, ovarian function, and raises the likelihood of pregnancy among patients with hormone receptor–negative
Previous analysis of the SWOG S0230/POEMS study suggested that goserelin improves survival rates, ovarian function, and raises the likelihood of pregnancy among patients with hormone receptor–negative
The following article features coverage from the San Antonio Breast Cancer Symposium (SABCS) 2017 meeting. Click here to read more of Cancer Therapy Advisor's conference coverage.

Adding goserelin to a standard chemotherapy regimen reduces the risk of ovarian failure and improves 5-year survival rates among patients with hormone receptor–negative breast cancer, according to research being presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).1

Previous analysis of the SWOG S0230/POEMS study (ClinicalTrials.gov Identifier: NCT00068601) suggested that goserelin, which suppresses estrogen production, improves survival rates, ovarian function, and raises the likelihood of future pregnancy among patients with hormone receptor–negative disease. Five-year follow-up data for survival are being presented at this year's SABCS.

Two hundred and fifty-seven patients were randomly assigned to receive goserelin plus a cyclophosphamide-containing chemotherapy regimen or chemotherapy alone; 218 patients (median age, 37.7 years) had evaluable data overall, 136 patients had evaluable data regarding ovarian failure, and 186 had menstrual data.

The estimated 5-year overall survival rates were 92% and 83% in the goserelin and standard chemotherapy groups, respectively; the estimated 5-year disease-free survival rates were 88% and 79% in the goserelin and standard chemotherapy groups, respectively.

After a median 5.1 years' follow-up, 22% of patients in the goserelin group and 12% of patients in the standard chemotherapy group had at least 1 pregnancy.

Patients in the goserelin group had a lower 2-year risk of ovarian failure (odds ratio, 0.3) and a 10% higher rate of menses-recovery.

The authors concluded that “goserelin during chemotherapy for hormone receptor–negative breast cancer reduces [ovarian failure] risk and, after 5 years of follow-up, continues to be associated with more pregnancies and improved survival compared with chemotherapy without goserelin.”

Read more of Cancer Therapy Advisor's coverage of the San Antonio Breast Cancer Symposium (SABCS) 2017 meeting by visiting the conference page.

Reference

  1. Moore HCF, Unger JM, Phillips KA, et al. Final analysis of SWOG S0230/Prevention of early menopause study (POEMS). Poster presentation at: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs